A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors. (Q54107114)

24 May 2018

title

A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors. (English)

1 reference

24 May 2018

main subject

elisidepsin

1 reference

ChEBI release 2020-05-28

1 reference

R Salazar

1

1 reference

24 May 2018

R J Jones

2

1 reference

24 May 2018

A Oaknin

3

1 reference

24 May 2018

D Crawford

4

1 reference

24 May 2018

C Cuadra

5

1 reference

24 May 2018

C Hopkins

6

1 reference

24 May 2018

M Gil

7

1 reference

24 May 2018

C Coronado

8

1 reference

24 May 2018

A Soto-Matos

9

1 reference

24 May 2018

M Cullell-Young

10

1 reference

24 May 2018

J L Iglesias Dios

11

1 reference

24 May 2018

T R J Evans

12

1 reference

24 May 2018

publication date

25 August 2012

1 reference

24 May 2018

Cancer Chemotherapy and Pharmacology

published in

1 reference

24 May 2018

volume

70

1 reference

24 May 2018

page(s)

673-681

1 reference

24 May 2018

issue

5

1 reference

24 May 2018

https://scigraph.springernature.com/pub.10.1007/s00280-012-1951-6

exact match

0 references

cites work

Chemical and enzymatic stability of a cyclic depsipeptide, the novel, marine-derived, anti-cancer agent kahalalide F.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1951-6

Cancer treatments: can we find treasures at the bottom of the sea?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1951-6

Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1951-6

Levels of SCS7/FA2H-mediated fatty acid 2-hydroxylation determine the sensitivity of cells to antitumor PM02734.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1951-6

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1951-6

Requirement of sphingolipid alpha-hydroxylation for fungicidal action of syringomycin E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1951-6

Functions of lipid rafts in biological membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1951-6

Irvalec inserts into the plasma membrane causing rapid loss of integrity and necrotic cell death in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1951-6

The mechanism of action of Kahalalide F: variable cell permeability in human hepatoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1951-6

Kahalalide F, an antitumor depsipeptide in clinical trials, and its analogues as effective antileishmanial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1951-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1951-6

Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1951-6

Phase II study of weekly Kahalalide F in patients with advanced malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1951-6

Phase I Clinical and Pharmacokinetic Study of Kahalalide F Administered Weekly as a 1-Hour Infusion to Patients with Advanced Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1951-6

10.1007/S00280-012-1951-6

21 January 2018

Identifiers

DOI

1 reference

24 May 2018

PubMed ID

22926637

1 reference

24 May 2018